BSE filing, NSE: GUJALKALI. Summary written from the filing by ALFA Finder's alert engine.
Gujarat Alkalies & Chemicals Ltd: key numbers
- Share price
- ₹552.40
- Market cap
- ₹4,057 Cr
- Revenue (annual)
- ₹4,358 Cr
- Net profit (annual)
- ₹-2.41 Cr
- P/E (TTM)
- 61.1×Sector 34.1×
- Promoter holding
- 47.28%+0.00% QoQ
- FII holding
- 3.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gujarat Alkalies & Chemicals Ltd
All →Gujarat Alkalies & Chemicals Board Meeting Date
GACL notified a board meeting on 5 November 2026 to consider Q2 and H1 FY27 provisional results. The trading window will remain closed until 7 November 2026.
Gujarat Alkalies & Chemicals Capacity Expansion
GACL conducted the ground-breaking ceremony of its 33,870 TPA food-grade phosphoric acid plant PPA-II at Dahej. The facility marks the start of construction for capacity expansion.
- phosphoric acid production capacity
- 33870 TPA
Gujarat Alkalies & Chemicals Other Announcement
Gujarat Alkalies and Chemicals Limited has published newspaper advertisements regarding a special window for the transfer and dematerialization of physical securities as per SEBI regulations.
Gujarat Alkalies & Chemicals Other Announcement
Gujarat Alkalies and Chemicals Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended 30 September 2026.
Gujarat Alkalies & Chemicals Annual General Meeting
Gujarat Alkalies and Chemicals Limited conducted its 53rd Annual General Meeting on September 25, 2026. Members considered dividend declaration and approval of material related party transactions.
Gujarat Alkalies & Chemicals Business Update
Gujarat Alkalies and Chemicals Limited has submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's ESG performance and operational metrics.
Other board meeting date announcements
All →Patel Engineering Board Meeting Date
Patel Engineering has scheduled its Board meeting for November 5, 2026, to approve Q1 and H1 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
GKB Ophthalmics Board Meeting Date
GKB Ophthalmics scheduled its Board Meeting for November 12, 2026. The meeting will consider approving unaudited results for the September 30, 2026 quarter and half year.
Bombay Oxygen Investments Board Meeting Date
Board meeting scheduled for Nov 6, 2026 to approve Q1 and H1 FY27 unaudited results. Trading window closed for insiders Oct 1–Nov 8, 2026.
OCCL Board Meeting Date
OCCL Ltd has scheduled its Board meeting for 6 November 2026 to consider Q1 FY27 unaudited results and a possible interim dividend. The trading window for designated persons closed from 1 October 2026.
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.